2026-03-11T22:13:25Z https://asahikawa-med.repo.nii.ac.jp/oai

oai:asahikawa-med.repo.nii.ac.jp:00006070 2023-06-19T12:03:37Z 7 7:24

Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome. 野津, 司 ノヅ, ツカサ 宮岸, 沙織 ミヤギシ, サオリ 野津, 麟太郎 ノヅ, リンタロウ 高草木, 薫 タカクサキ, カオル 奥村, 利勝 オクムラ, トシカツ Gut permeability Pioglitazone Visceral sensation PMID：30522964 Visceral hypersensitivity and impaired gut barrier with minor inflammation are considered to play an important role in the pathophysiology of irritable bowel syndrome (IBS). Since pioglitazone is known to have anti-inflammatory property, we hypothesized that pioglitazone is beneficial for treating IBS. In this study, the effect was tested in rat IBS models such as lipopolysaccharide or repeated water avoidance stress-induced visceral allodynia and increased colonic permeability. Pioglitazone blocked these visceral changes, and GW9662, a peroxisome proliferator-activated receptor gamma (PPAR-γ) antagonist fully reversed the effect by pioglitazone. These results suggest that PPAR-γ activation by pioglitazone may be useful for IBS treatment. an open access article under the CC BY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/) text application/pdf journal article 2019-01-01 VoR application/pdf Journal of Pharmacological Sciences 1 139 46 49 1347-8613 https://asahikawa-med.repo.nii.ac.jp/record/6070/files/7236.pdf https://asahikawa-med.repo.nii.ac.jp/records/6070 eng 10.1016/j.jphs.2018.11.006